Imagion Biosystems Statistics
Total Valuation
IBXXF has a market cap or net worth of 8.35 million. The enterprise value is 10.07 million.
| Market Cap | 8.35M |
| Enterprise Value | 10.07M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 468.14M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +295.60% |
| Shares Change (QoQ) | +251.56% |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | 1.29% |
| Float | 424.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.07 |
| PB Ratio | -3.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.97 |
| EV / Sales | 13.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.80 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -83.89% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 25.26% |
| Weighted Average Cost of Capital (WACC) | 8.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.45 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.43% in the last 52 weeks. The beta is -0.16, so IBXXF's price volatility has been lower than the market average.
| Beta (5Y) | -0.16 |
| 52-Week Price Change | -71.43% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 44.28 |
| Average Volume (20 Days) | 54,994 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IBXXF had revenue of 692,205 and -1.44 million in losses. Loss per share was -0.01.
| Revenue | 692,205 |
| Gross Profit | 246,537 |
| Operating Income | -640,242 |
| Pretax Income | -1.44M |
| Net Income | -1.44M |
| EBITDA | -858,156 |
| EBIT | -640,242 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 579,273 in cash and 2.16 million in debt, with a net cash position of -1.58 million.
| Cash & Cash Equivalents | 579,273 |
| Total Debt | 2.16M |
| Net Cash | -1.58M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -2.53M |
| Book Value Per Share | -0.01 |
| Working Capital | -2.54M |
Cash Flow
| Operating Cash Flow | -1.90M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 35.62%, with operating and profit margins of -92.49% and -208.52%.
| Gross Margin | 35.62% |
| Operating Margin | -92.49% |
| Pretax Margin | -208.52% |
| Profit Margin | -208.52% |
| EBITDA Margin | -123.97% |
| EBIT Margin | -92.49% |
| FCF Margin | n/a |
Dividends & Yields
IBXXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -295.60% |
| Shareholder Yield | -295.60% |
| Earnings Yield | -17.28% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 16, 2023. It was a reverse split with a ratio of 0.025.
| Last Split Date | Nov 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
IBXXF has an Altman Z-Score of -110.11 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -110.11 |
| Piotroski F-Score | 1 |